- Home
- CPRX vs KNSA Comparison
CPRX vs KNSA Comparison
Compare CPRX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- KNSA
- Stock Information
- Founded
- CPRX 2002
- KNSA 2015
- Country
- CPRX United States
- KNSA United Kingdom
- Employees
- CPRX N/A
- KNSA N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- CPRX Health Care
- KNSA Health Care
- Exchange
- CPRX Nasdaq
- KNSA Nasdaq
- Market Cap
- CPRX 2.6B
- KNSA 2.6B
- IPO Year
- CPRX 2006
- KNSA 2018
- Fundamental
- Price
- CPRX $20.02
- KNSA $35.43
- Analyst Decision
- CPRX Strong Buy
- KNSA Strong Buy
- Analyst Count
- CPRX 5
- KNSA 6
- Target Price
- CPRX $33.20
- KNSA $40.83
- AVG Volume (30 Days)
- CPRX 1.5M
- KNSA 402.6K
- Earning Date
- CPRX 11-05-2025
- KNSA 10-28-2025
- Dividend Yield
- CPRX N/A
- KNSA N/A
- EPS Growth
- CPRX 183.96
- KNSA N/A
- EPS
- CPRX 1.65
- KNSA 0.07
- Revenue
- CPRX $558,499,000.00
- KNSA $529,332,000.00
- Revenue This Year
- CPRX $16.51
- KNSA $37.21
- Revenue Next Year
- CPRX $9.58
- KNSA $11.99
- P/E Ratio
- CPRX $12.10
- KNSA $538.95
- Revenue Growth
- CPRX 28.55
- KNSA 56.18
- 52 Week Low
- CPRX $19.15
- KNSA $17.82
- 52 Week High
- CPRX $26.58
- KNSA $37.34
- Technical
- Relative Strength Index (RSI)
- CPRX 46.35
- KNSA 57.08
- Support Level
- CPRX $19.66
- KNSA $35.72
- Resistance Level
- CPRX $20.52
- KNSA $37.34
- Average True Range (ATR)
- CPRX 0.67
- KNSA 1.01
- MACD
- CPRX 0.03
- KNSA -0.12
- Stochastic Oscillator
- CPRX 42.08
- KNSA 53.31
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.